Oncimmune Germany Gmbh

Protagen Ag

Protagen Gmbh

Electrophoretics Limited

Petra Budde

Ian Hugo Pike

Karsten Kuhn

Angelika Lüking

Peter Schulz-Knappe

Hans-Dieter Zucht

Martin Gamer

Carmen Theek

Anna Telaar

Matthias Schneider

Dieter Zucht

Stephan Jung

Sasa Koncarevic

Stefan Selzer

Angelika LÜKING

The present invention relates to methods for identifying markers for systemic lupus erythematosus (SLE) and to the markers identified with the aid of this method, which can differentiate between SLE and other autoimmune diseases on the one hand and between different SLE subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in SLE. The invention also relates to methods for screening and validating active substances for application in SLE subgroups.

Marker sequences for diagnosing and stratifying SLE patients

The present invention relates to methods for identifying markers for systemic sclerosis (also scleroderma; SSc) and to the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc.

Marker sequences for diagnosing and stratifying systemic sclerosis patients

The present invention relates to methods for identifying markers for systemic sclerosis (also referred to as scleroderma; SSc) and the markers identified with the aid of this method, which can differentiate between SSc and other autoimmune diseases on the one hand and between different SSc subgroups on the other hand. The invention also relates to panels, diagnostic devices, and test kits which comprise these markers, and also to the use and application thereof, for example for the diagnosis, prognosis and therapy control of SSc. The invention also relates to methods for screening and for validating active substances for use in SSc subgroups.

Marker sequences for the diagnosis and stratification of systemic sclerosis patients

Growing community of inventors

Dortmund, Germany

Petra Budde